PASSAGE BIO, INC. Operating Lease, Expense
PASSAGE BIO, INC. (PASG) reported Operating Lease, Expense of $800.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-13
- PASSAGE BIO, INC. operating lease, expense for the quarter ending 2023-09-30 was $800.00K, a 0.00% change year-over-year.
- PASSAGE BIO, INC. operating lease, expense for the quarter ending 2023-06-30 was $800.00K, a 0.00% change year-over-year.
- PASSAGE BIO, INC. operating lease, expense for the quarter ending 2023-03-31 was $800.00K, a 0.00% change year-over-year.
- PASSAGE BIO, INC. operating lease, expense for the quarter ending 2022-09-30 was $800.00K, a 0.00% change year-over-year.
- PASSAGE BIO, INC. operating lease, expense for fiscal 2021 was $3.40M, a 466.67% increase from fiscal 2020.
- PASSAGE BIO, INC. operating lease, expense for fiscal 2020 was $600.00K, a 200.00% increase from fiscal 2019.
- PASSAGE BIO, INC. operating lease, expense for fiscal 2019 was $200.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | $800.00K 10-Q · filed 2023-11-13 | $1.60M derived: sum of 2 quarters · filed 2023-11-13 | $2.50M 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $800.00K 10-Q · filed 2023-08-07 | $1.70M 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $800.00K 10-Q · filed 2023-05-11 | ||||
| 2022-09-30 | $800.00K 10-Q · filed 2023-11-13 | $1.60M derived: sum of 2 quarters · filed 2023-11-13 | $2.50M 10-Q · filed 2023-11-13 | $3.30M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $800.00K 10-Q · filed 2023-08-07 | $900.00K 10-Q · filed 2022-08-04 | $1.70M 10-Q · filed 2023-08-07 | $2.50M derived: sum of 3 quarters · filed 2023-08-07 | $3.30M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $800.00K 10-Q · filed 2023-05-11 | $1.70M derived: sum of 2 quarters · filed 2023-05-11 | $2.50M derived: sum of 3 quarters · filed 2023-05-11 | $3.40M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.70M derived: sum of 2 quarters · filed 2022-11-10 | $2.60M derived: sum of 3 quarters · filed 2022-11-10 | $3.40M 10-K · filed 2022-03-03 | |
| 2021-09-30 | $800.00K 10-Q · filed 2022-11-10 | $1.70M derived: sum of 2 quarters · filed 2022-11-10 | $2.50M 10-Q · filed 2022-11-10 | $2.80M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $900.00K 10-Q · filed 2022-08-04 | $1.70M 10-Q · filed 2022-08-04 | $2.00M derived: sum of 3 quarters · filed 2022-08-04 | $2.20M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $800.00K 10-Q · filed 2022-05-16 | $1.10M derived: sum of 2 quarters · filed 2022-05-16 | $1.30M derived: sum of 3 quarters · filed 2022-05-16 | $1.40M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $500.00K derived: sum of 2 quarters · filed 2022-03-03 | $600.00K derived: sum of 3 quarters · filed 2022-03-03 | $600.00K 10-K · filed 2022-03-03 | |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-04 | $300.00K derived: sum of 2 quarters · filed 2021-11-04 | $300.00K 10-Q · filed 2021-11-04 | $436.00K derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-05 | $100.00K 10-Q · filed 2021-08-05 | $236.00K derived: sum of 3 quarters · filed 2021-08-05 | $286.00K derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $36.00K 10-Q · filed 2021-05-05 | $136.00K derived: sum of 2 quarters · filed 2021-05-05 | $186.00K derived: sum of 3 quarters · filed 2021-05-05 | $222.00K derived: sum of 4 quarters · filed 2021-05-05 | |
| 2019-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $150.00K derived: sum of 2 quarters · filed 2021-03-03 | $186.00K derived: sum of 3 quarters · filed 2021-03-03 | $200.00K 10-K · filed 2021-03-03 | |
| 2019-09-30 | $50.00K 10-Q · filed 2020-11-10 | $86.00K derived: sum of 2 quarters · filed 2020-11-10 | $100.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $36.00K 10-Q · filed 2020-08-13 | $87.00K 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | $51.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |